[VIRTUAL] PRIMARY RESULTS OF A PHASE 1 MULTICENTER OPEN-LABEL STUDY OF AK002, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS AND ELEVATED GASTRIC AND/OR DUODENAL MAST CELLS.

lirentelimab (AK002) - Allakos

https://members.naspghan.org/Annualmeeting/Program/Scientific_Abstracts_2020/Annualmeet[…]c_Abstracts.aspx?hkey=20f56992-f44b-42e0-b030-6e02e2a5c301

Dr. Adam Bledsoe1; Dr. Sabine Hazan9; Dr. Robert Genta2; Gary Falk3; Dr. Joseph Murray1; Dr. Kenneth Boren4; Kathryn Peterson5; Malika Pasha6; Dr. Bhupinder Singh6; Alan Chang6; Dr. Amol Kamboj6; Dr. Henrik Rasmussen6; Ikuo Hirano7; Evan Dellon8

Jan 24, 2021